NCT06838429尚未招募不适用
Effect of PARP Inhibitors Maintenance Therapy on the Survival Rate of Advanced or Relapsed Epitherlial Ovarian Cancer: an Observational Cohort Study
Shanghai Gynecologic Oncology Group0 个研究点目标入组 6,000 人开始时间: 2025年3月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 6,000
- 主要终点
- Overall Mortality
研究概览
简要总结
With the widespread use of PARP inhibitors (PARPi) as maintenance therapy in ovarian cancer, there is still a lack of real-world data from large samples regarding their impact on survival outcomes in advanced and recurrent ovarian cancer. This study aims to conduct a pragmatic cohort study to evaluate the impact of first-line and second-line maintenance treatment with PARPi on survival rates in patients with advanced and recurrent ovarian cancer. The genetic status, different PARPi drugs, and the use of anti-angiogenic inhibitor maintenance therapy or not is used as confounding factors.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients newly diagnosed with stage IIIC or IV primary epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer between December 2013 and December
- •Complete data on first-line treatment and maintenance therapy.
- •Availability of follow-up data.
- •Patients with platinum-sensitive first recurrence of any stage of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, diagnosed between December 2013 and December
- •Disease progression occurring at least 6 months after the completion of the last platinum-based chemotherapy regimen.
- •Complete data on second-line treatment and maintenance therapy.
- •Availability of follow-up data.
排除标准
- •Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
- •Missing first-line or follow-up data.
- •Non-epithelial tumors, borderline tumors, clear cell carcinoma, mucinous carcinoma.
- •Patients with second relapse.
- •Platinum-resistant patients, such as those who had disease progression during chemotherapy or within 6 months after platinum-based chemotherapy.
- •Missing second-line or follow-up data.
结局指标
主要结局
Overall Mortality
时间窗: 11 years
Mortality of any cause
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR InhibitorsOvarian CancerNCT05640024Yonsei University54
招募中
不适用
Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Ovarian CancerNCT05458973Yonsei University100
尚未招募
2 期
Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance PatientsOvarian CancerNCT06544460Fudan University94
招募中
2 期
Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPiOvarian CancerNCT05551208Chongqing University Cancer Hospital42
Unknown
2 期
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerNeoplasms by SiteBRCA1 MutationAngiogenesisAntineoplastic AgentsBRCA2 MutationAnlotinibOvarian and Fallopian Tube Cysts and NeoplasmsPARP InhibitorsNeoplasmsGenital Neoplasms, FemaleUrogenital NeoplasmsNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeCarcinoma, Ovarian EpithelialOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleCarcinomaOvarian CancerNCT04566952Xiaoxiang Chen68